PP_1170x120_10-25-21

Takeda

Evotec and Takeda ink research deal

Evotec and Takeda ink research deal

HAMBURG, Germany — Evotec SE announced that Evotec GT, with operations in Austria, has established a long-term research alliance with Takeda to support Takeda’s growing number of research stage gene therapy discovery programs. Evotec GT is an integral part of Evotec’s integrated fully modality-agnostic drug discovery platform that combines all activities involved with the discovery,

AstraZeneca buys Takeda respiratory business

AstraZeneca buys Takeda respiratory business

LONDON and OSAKA, Japan — AstraZeneca plans to acquire the core respiratory business of Takeda Pharmaceutical Co. Ltd. for $575 million. Under the agreement, approximately 200 Takeda staff will transfer to AstraZeneca after the closing of the transaction, expected in the first quarter of 2016. AstraZeneca said the deal will include the expansion of rights

Takeda’s Ninlaro becomes available in U.S.

Takeda’s Ninlaro becomes available in U.S.

CAMBRIDGE, Mass. — Takeda Pharmaceutical Co. has released Ninlaro capsules (ixazomib), a blood cancer medication, in the United States. Takeda said Friday that Ninlaro is the first and only oral proteasome inhibitor. In combination with lenalidomide and dexamethasone, Ninlaro is indicated for the treatment of patients with multiple myeloma, a plasma cell cancer, who have received at least one

Adheris Health